These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33881612)

  • 1. TREM2 expression in the brain and biological fluids in prion diseases.
    Diaz-Lucena D; Kruse N; Thüne K; Schmitz M; Villar-Piqué A; da Cunha JEG; Hermann P; López-Pérez Ó; Andrés-Benito P; Ladogana A; Calero M; Vidal E; Riggert J; Pineau H; Sim V; Zetterberg H; Blennow K; Del Río JA; Marín-Moreno A; Espinosa JC; Torres JM; Sánchez-Valle R; Mollenhauer B; Ferrer I; Zerr I; Llorens F
    Acta Neuropathol; 2021 Jun; 141(6):841-859. PubMed ID: 33881612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TREM2: Innocent bystander or active player in neurological diseases?
    Filipello F; Goldsbury C; You SF; Locca A; Karch CM; Piccio L
    Neurobiol Dis; 2022 Apr; 165():105630. PubMed ID: 35041990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
    Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
    Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
    Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
    Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.
    Bekris LM; Khrestian M; Dyne E; Shao Y; Pillai JA; Rao SM; Bemiller SM; Lamb B; Fernandez HH; Leverenz JB
    J Neuroimmunol; 2018 Jun; 319():19-27. PubMed ID: 29685286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
    Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
    Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease.
    Llorens F; Zafar S; Ansoleaga B; Shafiq M; Blanco R; Carmona M; Grau-Rivera O; Nos C; Gelpí E; Del Río JA; Zerr I; Ferrer I
    Neuropathol Appl Neurobiol; 2015 Aug; 41(5):631-45. PubMed ID: 25134744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.
    Zhang X; Tang L; Yang J; Meng L; Chen J; Zhou L; Wang J; Xiong M; Zhang Z
    Nat Commun; 2023 Oct; 14(1):6670. PubMed ID: 37865646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The
    Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
    Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
    Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
    Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
    Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
    Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
    Qin C; Chen M; Dong MH; Yang S; Zhang H; You YF; Zhou LQ; Chu YH; Tang Y; Pang XW; Wu LJ; Tian DS; Wang W
    Brain; 2024 Jan; 147(1):163-176. PubMed ID: 37740498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease.
    Zerr I; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Ferrer I; Riggert J; Zetterberg H; Blennow K; Llorens F
    Alzheimers Res Ther; 2021 Apr; 13(1):86. PubMed ID: 33883011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases.
    Villar-Piqué A; Schmitz M; Lachmann I; Karch A; Calero O; Stehmann C; Sarros S; Ladogana A; Poleggi A; Santana I; Ferrer I; Mitrova E; Žáková D; Pocchiari M; Baldeiras I; Calero M; Collins SJ; Geschwind MD; Sánchez-Valle R; Zerr I; Llorens F
    Mol Neurobiol; 2019 Apr; 56(4):2811-2821. PubMed ID: 30062673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.